Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901469 · ClinicalTrials.gov registry record · Phase 2
A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
A Phase 2 study, sponsored by Zenith Epigenetics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT03901469 is a Phase 2 study that was terminated before completion, run by Zenith Epigenetics. The registered enrollment target is 115 participants.
The verdict
NCT03901469, a Phase 2 study, was terminated before completion, sponsored by Zenith Epigenetics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combination treatment in post-TROP2-ADC patients), Expansion Cohort B (ZEN003694 monotherapy), and Expansion Cohort C (combination treatment in TROP2-ADC-naive patients).
Interventions
- DRUG Talazoparib
- DRUG ZEN003694
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2019-06-26 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03901469
The ClinicalTrials.gov registry entry for NCT03901469 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Zenith Epigenetics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Talazoparib is the first listed.
NCT03901469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03901469 about?
NCT03901469 is a clinical study titled "A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer". This is a two-part open label, non-randomized, Phase 2, study of ZEN003694 in combination with Talazoparib in patients with TNBC without germline mutations of BRCA1 or BRCA2. Part 1 is a dose escalation and Part 2 is a Simon 2-Stage design. There are 3 expansion cohorts: Expansion Cohort A (combinat...
What is the current status of trial NCT03901469?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2019-06-26. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT03901469?
The interventions under investigation include: Talazoparib (DRUG), ZEN003694 (DRUG).
Who is sponsoring clinical trial NCT03901469?
This trial is sponsored by Zenith Epigenetics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.